NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) Stock Profile — Insider Trades & Financials

EPS$-2.48

Market Cap$128.1M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Amir Heshmatpour

CEO & Executive Director

NeOnc Technologies Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for intracranial malignancies. Its lead product candidates include NEO100, a purified form of preillyl acid that is in Phase IIa clinical trial; and NEO212, a covalently conjugated molecule combining chemotherapeutic drug temozolomide with perillyl alcohol that is in Phase I/II clinical trials for its oral administration for the treatment of primary brain cancers, such as meningioma, high grade gliomas, glioblastoma, and secondary brain cancers. The company was formerly known as NAS-ONC, Inc. and changed its name to NeOnc Technologies Holdings, Inc. in 2009. The company was incorporated in 2005 and is headquartered in Calabasas, California.

Founded: 2008
Employees: 8
Headquarters

⚡

Core Efficiency

D/E Ratio?

-1.16

📊

Profitability Ratios

Current Ratio?

0.07

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 29, 2026 (in 142 days)

Annual Report (10-K) — Estimated

Aug 29, 2026

Predicted10-K

Mar 31, 2026

10-KQ4 20251d after period end

Nov 14, 2025

10-QQ3 20250d after period end

Aug 18, 2025

10-QQ2 20250d after period end

May 9, 2025

10-QQ1 20250d after period end

Data Freshness

Financial Data

4 days ago

Latest filing: 2026-03-31

SEC Metadata

17 days ago

Latest filing: 2025-05-09